AZD3839 (free base) is a potent and selective BACE1 inhibitor with IC50 of 23.6 uM, about 14-fold selectivity over BACE2, also a β-secretase enzyme inhibitor.target: BACE1, β-secretase enzyme [1]IC50: 23.6 uM [1]AZD3839 dissolved in 0.33% dimethylsulfoxideIn vitro: AZD3839 and its metabolites M1 and M2 inhibited CYP3A4 in a reversible and an irreversible manner, which could affect not only the metabolism of other CYP3A4 substrates but also the metabolism of AZD3839 itself. [1]In vivo: AZD3839 is dissolved in 0.3 M gluconic acid, adjusted to pH 3. Solutions of 0.75, 2.5, and 7.5 mg/ml are prepared and are administered orally by gavage at 2 ml/kg body weight at 1.5, 5, and 15 mg/kg (study 1) and 15 mg/kg (study 2). [1]AZD3839 effectively reduces the levels of Aβ in brain, CSF, and plasma in several preclinical species. [2]
Clofarabine(Clolar; Clofarex) inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.IC50 Value: 65 nMTarget: in vitro: Clofarabine is a second generation purine nucleoside analog with antineoplastic activity. It is phosphorylated intracellularly, which inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factor, which activate apoptosis.in vivo: Clofarabine is used for treating relapsed or refractory acute lymphoblastic leukaemia (ALL) in children, after at least two other types of treatment have failed.
5-Methyl-2-thio-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
Aclacinomycin A hydrochloride (Aclarubicin hydrochloride), a fluorescent molecule, is an effective anthracycline chemotherapeutic agent for hematologic cancers and solid tumors. Accumulates efficiently in the mitochondria of living human cells and leads to mitochondrial dysfunction[1].
Saikosaponin B2 is an active component from Bupleurum kaoi root, acts as an entry inhibitor against HCV infection[1]. Anti-cancer activity[2].
Trifluridine-tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug that consists of an antineoplastic thymidine-based nucleoside analog, trifluorothymidine, and a potent thymidine phosphorylase inhibitor, tipiracil, in a 1:0.5 molar ratio.
KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737)[1].
Rintodestrant (G1T48) is an orally active, non-steroidal and selective estrogen receptor degrader. Rintodestrant (G1T48) is also a CDK4/6 inhibitor[1].
Glutaminase-IN-1, a CB839 derivative, is an allosteric inhibitor of 1,3,4-selenadiazole-containing kidney-type glutaminase (KGA), with an IC50 of 1 nM. Glutaminase-IN-1 shows improved cellular uptake and antitumor activity.
3CAI is a potent and specific AKT1 and AKT2 inhibitor.
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
IPI549 is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM.
Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist; abolishes exogenous Wnt5a stimulation of A2058 cells increased adhesion, migration and invasion, all crucial components of tumor metastasis, also inhibits the basal migration and invasion of Wnt5a-expressing HTB63 melanoma cells, antagonizes the effects of Wnt5a on melanoma cell migration and invasion by directly inhibiting Wnt5a-induced PKC and Ca(2+) signaling.
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL)[1].
ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects .
2’,3’,5’-Tri-O-benzyl-4’-thio-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1].
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1].
Antroquinonol ((+)-Antroquinonol), a ubiquinone derivative from the mushroom Antrodia camphorata, has hepatoprotective, anti-inflammatory, and anti-cancer effects[1]. Antroquinonol can be used for the research of colon cancer[2]. Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice[3].
RTC-30 is an optimized phenothiazine with anti-cancer potency. RTC-30 contains a hydroxylated linker (N) that confers increased oral bioavailability[1].
Sec61-IN-1 is a potent sec61 inhibitor (Patent WO2020176863A1, compound A317)[1].
Ginsenoside Rg6 is the component isolated from notoginseng. Ginsenoside Rg6 inhibits TNF-α-induced NF-κB transcriptional activity with an IC50 of 29.34±2.22 μM in HepG2 cells. Ginsenoside Rg6 also exhibits apoptosis-inducing effect.
ICG-OSu (ICG NHS ester), a near-infrared fluorescent agent, is amine-reactive and has been widely used to design in vivo imaging probes[1].
Chlorogenic acid butyl ester, a caffeoylquinic acid, is a potent melanogenesis inhibitor. Chlorogenic acid butyl ester inhibits the expression of microphtalmia-associated transcription factor (MITF), tyrosinase, tyrosinerelated protein 1 (TRP-1), and TRP-2. Chlorogenic acid butyl ester also shows antioxidant activity[1].
ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1)[1].
3-O-Acetylbufotalin is a derivate of bufadienolide, with anti-cancer activity[1].
ODN MT 01 is a synthetic oligodeoxynucleotide. ODN MT 01 can be used for experiment research[1][2].
USP22-IN-1 (compound S02) is a potent USP22 inhibitor. USP22-IN-1 decreases the expression of FOXP3, USP22 protein and Foxp3 mRNA levels. USP22-IN-1 enhanceds anti -tumor immunity[1].
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer[1].
Carvedilol-d5 is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].
TBHQ is an antioxidant that activates Nrf2.